Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.
Norio ItokawaMasanori AtsukawaAkihito TsubotaToru IshikawaHidenori ToyodaKoichi TakaguchiTsunamasa WatanabeChikara OgawaAtsushi HiraokaHironao OkuboHaruki UojimaMakoto ChumaAkito NozakiKeizo KatoShigeru MikamiJoji TaniAsahiro MorishitaToshifumi TadaToru AsanoTomonori SenohTsunekazu OikawaTomomi OkuboTakashi KumadaKatsuhiko IwakiriPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2024)
In TAF monotherapy for patients with chronic hepatitis B, HBcrAg levels were significantly decreased and baseline alanine transaminase level is an important factor associated with HBcrAg reduction. As no correlation was found between HBcrAg and reduced hepatitis B surface antigen levels in this study, HBcrAg kinetics in addition to hepatitis B surface antigen may need to be monitored during TAF treatment.